What distinguishes Ipamorelin from earlier GHRPs (such as GHRP-2 and GHRP-6) is its receptor selectivity. Published research has consistently characterized Ipamorelin as one of the cleanest GHSR-1a agonists available, with minimal documented effect on cortisol, prolactin, ACTH, or aldosterone secretion at comparable GH-releasing doses. This selectivity makes it a valuable tool compound for investigators who want to isolate ghrelin-receptor-mediated GH signaling from the confounding endocrine effects associated with less selective secretagogues.
Common research applications include: in vitro studies on GHSR-1a receptor binding and downstream cAMP/IP3 signaling, pituitary cell-culture assays measuring GH release dynamics, rodent models examining pulsatile growth hormone secretion, body composition and IGF-1 axis research, sleep architecture and slow-wave sleep studies (GH is closely tied to deep sleep), and comparative pharmacology benchmarking Ipamorelin against GHRP-2, GHRP-6, Hexarelin, and CJC-1295. It is also frequently studied in combination with GHRH analogs such as CJC-1295 to investigate synergistic GH pulse amplification.
Hydra Pulse Research Ipamorelin ships as a sterile lyophilized powder in a tamper-evident vial, accompanied by a Certificate of Analysis documenting peptide identity, molecular mass, and HPLC purity. Each lot is independently tested before release, and we maintain full batch traceability for documentation and audit purposes. Our manufacturing partners operate under ISO standards, and we do not source from unverified intermediaries.




